{"entity":{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","aka":[],"tldr":"Repare Therapeutics was a Montreal cancer drug developer working on drugs that stop tumours repairing their own DNA. In January 2026 it was bought by a non-profit called XenoTherapeutics and its shares stopped trading.","summary":"Repare Therapeutics was a clinical-stage precision oncology company based in Cambridge, Massachusetts and Montreal, focused on synthetic lethal targets in the DNA damage response. Its portfolio included camonsertib (RP-3500, an ATR inhibitor), lunresertib (RP-6306, a PKMYT1 inhibitor), RP-1664 (PLK4) and RP-3467 (Pol theta), with partnerships involving Bristol Myers Squibb, Debiopharm and DCx Biotherapeutics. After a strategic review, Repare agreed in November 2025 to be acquired by XenoTherapeutics, Inc., a non-profit biotechnology company, by way of a plan of arrangement. Shareholders approved the deal on 16 January 2026 and it completed on 28 January 2026, with holders receiving about 2.20 US dollars per share plus a contingent value right tied to future partnership and licensing proceeds. The company then delisted from Nasdaq and filed to deregister in February 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.reparerx.com/"},{"label":"Acquisition agreement announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525283314/d39095dex991.htm"},{"label":"Completion of acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/d95398dex991.htm"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["synthetic-lethality-approaches"],"targets":["atr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company website (reparerx.com) could not be fetched (TLS handshake failure and HTTP 409) and the investor site returned 403, so the website URL is unverified. Former Nasdaq ticker RPTX omitted because the shares no longer trade. Pipeline details are taken from the acquisition press release; the IPO (2020) was not sourced."],"hq":"Montreal","country":"CA","companyType":"biotech","website":"https://www.reparerx.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2026,"source":"https://www.sec.gov/Archives/edgar/data/1808158/000119312526027394/d95398dex991.htm","note":"All shares acquired by non-profit XenoTherapeutics for about 2.20 US dollars per share in cash plus a contingent value right; total deal value not stated"}]},"route":"/companies/repare-therapeutics/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/"}]}}